CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
High ImpactOriginal article

AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal

Positive
AI Analysis

Summary

Eli Lilly acquired AtaiBeckley, a psychedelic biotech company, in a $2.8 billion deal, described as the industry's largest psychedelic biotech buyout. The acquisition followed competitive co-development and royalty offers from other companies.

Importance:8/10
Sentiment:
0.50
acquisitionpsychedelicM&ALilly
Related Companies

Read the original article

Published by Endpoints News on July 30, 2026 3:10 PM

Read Original